Pharmamarketeer

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a U-turn on its previous decision to reject the drug for being an ineffective use of NHS resources.

The recommendation, made after the manufacturer agreed to a confidential discount, will make the drug available on the health service specifically in locally advanced or metastatic NSCLC, that has tested positive for the epidermal growth factor receptor (EGFR) mutation.

read more

Advertentie(s)